Walleye Trading’s Arbutus Biopharma ABUS Stock Holding History

Walleye Trading’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.2K	Hold	14,000	–	–	﹤0.01%	3514
2026 Q1	$63K	Hold	14,000	–	–	﹤0.01%	3617
2025 Q4	$67.3K	Hold	14,000	–	–	﹤0.01%	3874
2025 Q3	$63.6K	Hold	14,000	–	–	﹤0.01%	3887
2025 Q2	$43.3K	Hold	14,000	–	–	﹤0.01%	3846
2025 Q1	$48.9K	Hold	14,000	–	–	﹤0.01%	3615
2024 Q4	$45.8K	Hold	14,000	–	–	﹤0.01%	3810
2024 Q3	$53.9K	Hold	14,000	–	–	﹤0.01%	3515
2024 Q2	$43.3K	Hold	14,000	–	–	﹤0.01%	3636
2024 Q1	$36.1K	Buy	+14,000	New	+$36.3K	﹤0.01%	4104
2022 Q1	–	Sell	-48,743	Closed	-$190K	–	5241
2021 Q4	$190K	Sell	48,743 -28,053	-37%	-$109K	﹤0.01%	3914
2021 Q3	$329K	Buy	+76,796	New	+$256K	﹤0.01%	3379
2019 Q4	–	Sell	-22,658	Closed	-$35K	–	4185
2019 Q3	$35K	Buy	+22,658	New	+$39K	﹤0.01%	3662
2018 Q4	–	Sell	-21,578	Closed	-$204K	–	4540
2018 Q3	$204K	Buy	+21,578	New	+$214K	﹤0.01%	3751
2017 Q1	–	Sell	-7,000	Closed	-$17K	–	4612
2016 Q4	$17K	Buy	+7,000	New	+$20.4K	﹤0.01%	4142

Other funds holding ABUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

FCH

Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return

LWA

Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return

CCA

Carrera Capital Advisors Troy, Michigan $675M AUM 17.92% 1-Year Est. Return

CCIA

Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Walleye Trading's ABUS Position: Q2 2026 in Review

Walleye Trading held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 14,000 shares worth $67.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3514.

Walleye Trading first reported a position in ABUS in Q4 2016 and has held it in 15 quarters since. The position peaked at $329K in Q3 2021. 51 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Walleye Trading held 14,000 shares of Arbutus Biopharma worth $67.2K as of Q2 2026.
Walleye Trading left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #3514 holding.
Walleye Trading first reported a position in Arbutus Biopharma in Q4 2016 and has held it in 15 quarters since.
Walleye Trading's Arbutus Biopharma position peaked at $329K in Q3 2021.
51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.